Art. -Nr.: HY-10012

AZD-5438

16 Cited Publications

Kundenbewertung

Based on 16 publication(s) in Google Scholar

AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 602306-29-6
Formel: C₁₈H₂₁N₅O₂S
Molecular Weight:371.46

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

AZD-5438 Chemical Structure

CAS. Nr.: 602306-29-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (16)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

cdk2-cyclin E

6 nM (IC₅₀)

cdk2-cyclin A

45 nM (IC₅₀)

cdk5-p25

14 nM (IC₅₀)

cdk1-cyclin B1

16 nM (IC₅₀)

cdk9-cyclin T

20 nM (IC₅₀)

cdk6-cyclin D3

21 nM (IC₅₀)

cdk4-cyclin D1

449 nM (IC₅₀)

cdk7-cyclin H

821 nM (IC₅₀)

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	GI₅₀	0.45 μM Compound: AZD5438	Growth inhibition of human HCT-116 cells incubated for 48 hrs by CCK-8 assay Growth inhibition of human HCT-116 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38488882]
HCT-116	IC₅₀	0.47 μM Compound: AZD5438	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 31254921]
HeLa	IC₅₀	0.73 μM Compound: AZD5438	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 31254921]
HeLa	IC₅₀	1.2 μM Compound: 6; MMV676604	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay	[PMID: 30647879]
HT-29	GI₅₀	0.96 μM Compound: AZD5438	Growth inhibition of human HT-29 cells incubated for 48 hrs by CCK-8 assay Growth inhibition of human HT-29 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38488882]
LoVo	IC₅₀	0.63 μM Compound: 6c, AZD-5438	Antiproliferative activity against human LoVo cells assessed as BrdU incorporation after 48 hrs Antiproliferative activity against human LoVo cells assessed as BrdU incorporation after 48 hrs	[PMID: 18815031]
LoVo	IC₅₀	0.8 μM Compound: 1, AZD-5438	Antiproliferative activity against human LoVo cells assessed as inhibition of BrdU incorporation after 48 hrs Antiproliferative activity against human LoVo cells assessed as inhibition of BrdU incorporation after 48 hrs	[PMID: 18996007]
LoVo	IC₅₀	0.8 μM Compound: 6	Antiproliferative activity against human LoVo cells assessed as inhibition of BrdU incorporation after 48 hrs Antiproliferative activity against human LoVo cells assessed as inhibition of BrdU incorporation after 48 hrs	[PMID: 18986805]
MCF7	IC₅₀	10.67 μM Compound: AZD5438	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 31254921]
MDA-MB-231	IC₅₀	7.2 μM Compound: AZD5438	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 31254921]
PC-3	IC₅₀	0.36 μM Compound: AZD5438	Antiproliferative activity against human PC3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 48 hrs by MTT assay	[PMID: 31254921]

In Vitro

AZD5438 potently inhibits the kinase activity of cyclin E-cdk2, cyclin A-cdk2, cyclin B1-cdk1, p25-cdk5, cyclin D3-cdk6, and cyclin T-cdk9 (IC₅₀, 6, 45, 16, 21, and 20 nM, respectively). AZD5438 potently inhibits the kinase activity of cyclin E-cdk2, cyclin A-cdk2, cyclin B1-cdk1, p25-cdk5, cyclin D3-cdk6, and cyclin T-cdk9 (IC₅₀, 6, 45, 16, 21, and 20 nM, respectively). In common with many other cdk inhibitors, AZD5438 also inhibits the kinase activity of p25-cdk5 and glycogen synthase kinase 3β in vitro (IC₅₀, 14 and 17 nM, respectively)^[1]. AZD5438 significantly augments cellular radiosensitivity in NSCLC cells. Combined treatment with AZD5438 and irradiation also enhances tumor growth delay, with an enhancement factor ranging from 1.2-1.7^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AZD5438 (50 mg/kg twice daily or 75 mg/kg, p.o.) inhibits human tumor xenograft growth. In vivo, AZD5438 reduces the proportion of actively cycling cells. Further pharmacodynamic analysis of AZD5438-treated SW620 xenografts shows that efficacious doses of AZD5438 (>40% tumor growth inhibition) maintains suppression of biomarkers, such as phospho-pRbSer249/Thr252, for up to 16 hours following a single oral dose^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 602306-29-6
Appearance Solid
Molecular Weight 371.46
Formel C₁₈H₂₁N₅O₂S
Color White to light yellow
SMILES

O=S(C1=CC=C(NC2=NC(C3=CN=C(N3C(C)C)C)=CC=N2)C=C1)(C)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (16)

All Cell Imaging/StainingWBApoptosis AnalysisIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

J Am Chem Soc

2026 Jun 3;148(23):24333-24344.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Exp Clin Cancer Res

Dual CDK and MEK Inhibition potentiates CD8+ T cell-mediated antitumor immunity by inducing pyroptotic cell death in high-mutational head and neck cancer. [Abstract]

2025 Nov 6;44(1):300. PMID: 41194215

AZD-5438 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 6;44(1):300. [Abstract]

Effect of AZD5438 (2 μM) and/or PD0325901 treatment on clonogenic ability of four HNSCC cell lines. HNSCC cells were treated with the drug for 10 days before analysis.

AZD-5438 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 6;44(1):300. [Abstract]

Effect of AZD5438 (2 μM) and/or PD0325901 treatment on the phosphorylation levels of ERK1/2 and Rb and c-PARP cleavage in Cal27 and HN12 cells.

AZD-5438 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 6;44(1):300. [Abstract]

Effect of AZD5438 (2 μM) and/or PD0325901 treatment on apoptosis of Cal27 and HN12 cells determined by Annexin V staining,

AZD-5438 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 6;44(1):300. [Abstract]

Tumor images in different treatment groups An orthotopic HN12 tumor model was established in the buccal mucosa of NSG mice, followed by oral administration of vehicle, PD0325901, AZD5438 (50 mg/kg, i.g.), or their combination once daily for 14 days.

AZD-5438 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 6;44(1):300. [Abstract]

Immunostaining of Ki67 and TUNEL assays for tumor tissues derived from the groups treated with vehicle, AZD5438, PD0325901, or the AZD5438 (50 mg/kg, i.g.) and PD0325901 combination.
Sci Adv

In silico transcriptome screens identify epidermal growth factor receptor inhibitors as therapeutics for noise-induced hearing loss. [Abstract]

Sci Adv. 2024 Jun 21;10(25):eadk2299. d PMID: 38896614
Sci Adv

A PSTAIRE-type cyclin-dependent kinase controls light responses in land plants. [Abstract]

2022 Jan 28;8(4):eabk2116. PMID: 35089781
J Am Soc Nephrol

Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced Acute Kidney Injury. [Abstract]

2024 Jan 1;35(1):22-40. PMID: 37962623
J Transl Med

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]

2022 Oct 2;20(1):444. PMID: 36184616
Oncogene

DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. [Abstract]

2026 Jun 10. PMID: 42270776
Cell Chem Biol

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. [Abstract]

2018 Feb 15;25(2):135-142.e5. PMID: 29276047
JACC Basic Transl Sci

Syntaxin 17 Protects Against Heart Failure Through Recruitment of CDK1 to Promote DRP1-Dependent Mitophagy. [Abstract]

2023 Jul 19;8(9):1215-1239. PMID: 37791317
Melanoma Res

LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization. [Abstract]

2022 Dec 1;32(6):419-427. PMID: 36094494
bioRxiv

2026 Jan 17.
SSRN

2025 Sep 19.
Sci Total Environ

Voltage-dependent anion channel 1 mediates mitochondrial fission and glucose metabolic reprogramming in response to ionizing radiation. [Abstract]

2024 Oct 10:946:174246. PMID: 38955266
University of Kiel

2023 Jul 20.
bioRxiv

In Silico Transcriptome-based Screens Identify Epidermal Growth Factor Receptor Inhibitors as Therapeutics for Noise-induced Hearing Loss. [Abstract]

2023 Jun 9:2023.06.07.544128. PMID: 37333346

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (269.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6921 mL

13.4604 mL

26.9208 mL

5 mM

0.5384 mL

2.6921 mL

5.3842 mL

10 mM

0.2692 mL

1.3460 mL

2.6921 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

AZD5438 is tested against solid tumor cell lines as previously described. Briefly, cells are incubated for 48 h with AZD5438 at a range of concentrations. At the end of incubation, the cells are pulsed with 5-bromo-2'-deoxyuridine (BrdUrd) and the amount of DNA synthesis is measured. The IC₅₀ for inhibition of proliferation is specifically determined independently of cell death. Multiple myeloma cell lines are seeded into 96-well plates in RPMI 1640 supplemented with 10% FCS and glutamine and dosed with AZD5438 for 72 h. Cell growth is measured using AlamarBlue and GI₅₀ values are calculated with reference to pretreatment control values.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

All human tumor xenografts except HX147 are established by s.c. injecting 100 μL of tumor cells (between 1×10⁶ and 1×10⁷ cells mixed 1:1 with Matrigel). HX147 tumors are derived from fragment implants (1 mm³ pieces) from tumors taken from mice initially implanted s.c. with 1×10⁷ cells. These tumor fragments are passaged in mice thrice before implant for antitumor work. Tumors are measured up to three times per week with calipers, tumor volumes are calculated, and the data are plotted as geometric mean for each group versus time, as previously described. Animals are randomized into treatment groups (typically n=10) when tumors reach a mean size of approximately >0.2 cm³ and >0.5 cm³ for mice and rats, respectively. AZD5438 is prepared in hydroxy-propyl-methyl-cellulose. Animals are given either AZD5438 (37.5-75 mg/kg) or vehicle control once or twice daily by oral gavage for appr 3 wk in each case. Tumor volume and percentage tumor growth inhibition (% TGI) are calculated as described previously. Statistical analysis of any change in tumor volume is carried out using a standard t test (P<0.05 is considered to be statistically significant).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Byth KF, et al. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. Epub 2009 Jun 9. [Content Brief]

[2]. Raghavan P, et al. AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells. Int J Radiat Oncol Biol Phys. 2012 Jul 12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6921 mL	13.4604 mL	26.9208 mL	67.3020 mL
	5 mM	0.5384 mL	2.6921 mL	5.3842 mL	13.4604 mL
	10 mM	0.2692 mL	1.3460 mL	2.6921 mL	6.7302 mL
	15 mM	0.1795 mL	0.8974 mL	1.7947 mL	4.4868 mL
	20 mM	0.1346 mL	0.6730 mL	1.3460 mL	3.3651 mL
	25 mM	0.1077 mL	0.5384 mL	1.0768 mL	2.6921 mL
	30 mM	0.0897 mL	0.4487 mL	0.8974 mL	2.2434 mL
	40 mM	0.0673 mL	0.3365 mL	0.6730 mL	1.6825 mL
	50 mM	0.0538 mL	0.2692 mL	0.5384 mL	1.3460 mL
	60 mM	0.0449 mL	0.2243 mL	0.4487 mL	1.1217 mL
	80 mM	0.0337 mL	0.1683 mL	0.3365 mL	0.8413 mL
	100 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6730 mL

Keywords

AZD-5438

16 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AZD-5438

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) AZD-5438

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AZD-5438

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) AZD-5438

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AZD-5438 Related Classifications

HY-10012 Related Classifications